StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Axsome Therapeutics's enterprise value was $7.67B on Nov 11, 2026, against $7.48B a year earlier. Over the last 5 years it ranged from $936.69M to $12.47B, with a median of $3.95B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$7.67B-15.2%
2025Dec 31, 2025$9.05B+129.1%
2024Dec 31, 2024$3.95B+12.0%
2023Dec 29, 2023$3.53B+9.7%
2022Dec 30, 2022$3.22B+136.7%
2021Dec 31, 2021$1.36B-53.0%
2020Dec 31, 2020$2.89B-18.5%
2019Dec 31, 2019$3.54B+5176.8%
2018Dec 31, 2018$67.12M-39.5%
2017Dec 29, 2017$110.95M+16.3%
2016Dec 30, 2016$95.40M+16.7%
2015Dec 31, 2015$81.73M–

More Axsome Therapeutics figures

See a number that looks wrong?